Prot#RIV-HU6-2201: NUECL for Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 in Subjects with Obese Heart Failure with Preserved Ejection Fra

Project: Research project

Project Details

StatusActive
Effective start/end date4/26/22 → 4/26/25

Funding

  • Rivus Pharmaceuticals, Inc. (Prot#RIV-HU6-2201)